8-K: XWELL Inc. Reports Strong First Quarter 2024 Results with Revenue Growth and Reduced Operating Losses

XWELL, Inc. announced a 24% year-over-year revenue increase and a 62% reduction in operating losses for the first quarter of 2024, demonstrating significant progress towards profitability.

Summary

• XWELL, Inc. reported its financial results for the first quarter of 2024, showing a 24% increase in revenue compared to the same period in 2023, reaching $8.7 million.
• The company's cost of sales decreased by approximately 7% year-over-year, while general and administrative expenses saw a significant reduction of approximately 47%.
• Total operating expenses decreased by approximately 26% compared to the first quarter of 2023.
• As a result of these improvements, XWELL's operating loss decreased by approximately 62%, from $6.3 million in Q1 2023 to approximately $2.4 million in Q1 2024.
• The net loss attributable to XWELL was approximately $2.5 million, compared to $5.5 million in the first quarter of 2023.
• XWELL's revenue for the quarter was primarily driven by $4.4 million from XpresSpa and Treat locations, $3.6 million from XpresTest (including biosurveillance and HyperPointe), and $0.6 million from Naples Wax Center.
• The company had approximately $4.3 million in cash and cash equivalents, and $14.8 million in marketable securities as of March 31, 2024, with no long-term debt.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, significant cost reductions, and a substantial decrease in operating losses. The company is also expanding its operations and has a strong balance sheet. However, the company is still reporting a net loss, which prevents a perfect score.

Positives

• XWELL demonstrated strong revenue growth of 24% year-over-year in the first quarter of 2024.
• The company significantly reduced its operating loss by 62% compared to the first quarter of 2023.
• XWELL has successfully reduced its cost structure, with a 7% decrease in cost of sales and a 47% decrease in general and administrative expenses.
• The expansion of the CDC's Traveler-based Genomic Surveillance program provides a stable revenue stream and demonstrates the company's capabilities in biosurveillance.
• The company is expanding its footprint with new locations for both XpresSpa and Naples Wax Center.
• XWELL has a strong balance sheet with $4.3 million in cash and cash equivalents and $14.8 million in marketable securities, and no long-term debt.

Negatives

• Despite significant improvements, XWELL still reported an operating loss of $2.4 million for the first quarter of 2024.
• The company reported a net loss of $2.5 million for the first quarter of 2024.

Risks

• The company's future performance is subject to risks and uncertainties, which could cause actual results to differ materially from forward-looking statements.
• The company's success depends on its ability to execute its expansion plans and achieve profitability.
• The company's biosurveillance program is subject to government funding and could be impacted by changes in government priorities.
• The company's expansion into new locations and services may not be successful.

Future Outlook

XWELL is focused on long-term strategic priorities including delivering improved results, reaching profitability, expanding its wellness portfolio, opening its first TreatStudios location later this year, continuing its collaboration with global governments in biosecurity, and leveraging new retail products and technologies. The company also intends to open approximately 10 Naples Wax Center locations by early 2025.

Management Comments

• We believe that XWELLs first quarter operating performance demonstrates accelerated progress in our efforts to drive growth cost-effectively and return to profitability, commented Scott Milford, XWELLs Chief Executive Officer.
• We continue to see opportunities for better performance and achieved year-over-year first quarter 2024 revenue growth of 24% while cutting operating expenses by 26% and reducing our operating loss by 62%, each as compared to the first quarter of 2023.

Industry Context

XWELL's focus on travel wellness and biosurveillance aligns with growing trends in health and safety, and the company's expansion into transportation hubs and new service offerings positions it to capitalize on these trends. The company's biosurveillance work is also relevant in the context of global health security concerns.

Comparison to Industry Standards

• XWELL's 24% revenue growth is a strong performance compared to many companies in the retail and wellness sectors, which often see single-digit growth rates.
• The 62% reduction in operating loss is a significant improvement, indicating effective cost management and operational efficiency.
• Companies like Massage Envy and European Wax Center are competitors in the wellness space, but XWELL's focus on travel hubs and biosurveillance provides a unique market position.
• The expansion of the CDC's Traveler-based Genomic Surveillance program is a unique offering that sets XWELL apart from other wellness companies.

Stakeholder Impact

• Shareholders will likely view the improved financial results and growth prospects positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to more wellness services and locations.
• Suppliers may see increased demand for their products and services.
• Creditors will be reassured by the company's improved financial position.

Next Steps

• XWELL plans to open a new XpresSpa location in New York City's Penn Station this summer.
• The company intends to open three additional Naples Wax Center locations in 2024.
• XWELL plans to roll out new facial services in existing Naples Wax Center locations over the summer.
• The company intends to execute additional Florida leases for Naples Wax Center locations.
• XWELL plans to open its first TreatStudios location later this year.
• The company will continue its collaboration with global governments in biosecurity.
• XWELL will continue to leverage new retail products and technologies.

Key Dates

Keywords

XWELL, XpresSpa, Naples Wax Center, XpresCheck, HyperPointe, Financial Results, Biosurveillance, Travel Wellness, Genomic Surveillance, Operating Loss, Revenue Growth, Cost Reduction